Microbio Co., Ltd. (TPEX:4128)

Market Cap	8.26B -42.1%
Revenue (ttm)	1.94B +9.8%
Net Income	-691.94M
EPS	-1.18
Shares Out	588.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,018,391
Open	14.55
Previous Close	14.45
Day's Range	13.90 - 14.75
52-Week Range	13.95 - 27.50
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and health foods in Taiwan. It provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. The company is also involved in the sale of organic food and beverages; provision of technology development, transfer, and consulting services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd....

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4128

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error